Synergy Pharmaceuticals has signed an Asset Purchase Agreement with Bristol-Myers Squibb, acquiring the assets of FV-100, an oral nucleoside analogue in development for the treatment of shingles, a severe, painful skin rash caused by reactivation of the chickenpox virus.   A completed Phase IIa trial of FV-100 in shingles patients found 200 mg and 400 mg doses of the drug to be well tolerated and clinically meaningful reductions in time to resolution of pain and incidence of post-herpetic neural...